Literature DB >> 14971643

p53 expression in circulating lymphocytes of non-melanoma skin cancer patients from an arsenic contaminated region in Mexico. A pilot study.

Ana M Salazar1, Emma Calderón-Aranda, Mariano E Cebrián, Monserrat Sordo, Andrés Bendesky, Arístides Gómez-Muñoz, Leonor Acosta-Saavedra, Patricia Ostrosky-Wegman.   

Abstract

Arsenic is a common environmental toxicant and epidemiological studies associate arsenic exposure with various pathologic disorders and several types of cancer. Skin cancers are the most common arsenic-induced neoplasias and the prevalence of skin lesions has been reported to be significantly elevated in individuals exposed to arsenic via drinking water in Mexico. Being lymphocytes the main cells used for human monitoring, we evaluated the expression of p53 protein in the lymphocytes from 44 healthy individuals and 19 samples from individuals living in a chronic arsenicism endemic region. Of the latter group, 12 individuals had non-melanoma skin cancer and 9 of them expressed p53 in the circulating lymphocytes, whereas only one of the 7 non-cancer arsenic exposed individuals expressed it. In the healthy non-arsenic exposed group only one from 44 individuals expressed the protein. These results suggest a clear relationship between non-melanoma skin cancer and p53 expression in circulating lymphocytes. p53 expression in circulating lymphocytes should be evaluated as a potential biomarker of effect or susceptibility.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971643     DOI: 10.1023/b:mcbi.0000007258.33942.f8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  44 in total

Review 1.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

2.  Cytogenetic effects in human exposure to arsenic.

Authors:  M E Gonsebatt; L Vega; A M Salazar; R Montero; P Guzmán; J Blas; L M Del Razo; G García-Vargas; A Albores; M E Cebrián; M Kelsh; P Ostrosky-Wegman
Journal:  Mutat Res       Date:  1997-06       Impact factor: 2.433

3.  Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors.

Authors:  D R Germolec; J Spalding; G A Boorman; J L Wilmer; T Yoshida; P P Simeonova; A Bruccoleri; F Kayama; K Gaido; R Tennant; F Burleson; W Dong; R W Lang; M I Luster
Journal:  Mutat Res       Date:  1997-06       Impact factor: 2.433

4.  Induction of p53 protein expression by sodium arsenite.

Authors:  A M Salazar; P Ostrosky-Wegman; D Menéndez; E Miranda; A García-Carrancá; E Rojas
Journal:  Mutat Res       Date:  1997-11-28       Impact factor: 2.433

5.  Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers.

Authors:  C H Chang; R K Tsai; G S Chen; H S Yu; C Y Chai
Journal:  J Cutan Pathol       Date:  1998-10       Impact factor: 1.587

6.  Inorganic arsenic effects on human lymphocyte stimulation and proliferation.

Authors:  M E Gonsebatt; L Vega; L A Herrera; R Montero; E Rojas; M E Cebrián; P Ostrosky-Wegman
Journal:  Mutat Res       Date:  1992-10       Impact factor: 2.433

7.  The oxidation states of arsenic in well-water from a chronic arsenicism area of northern Mexico.

Authors:  L M Del Razo; M A Arellano; M E Cebrián
Journal:  Environ Pollut       Date:  1990       Impact factor: 8.071

Review 8.  Tumors of the immunocompromised patient.

Authors:  I Penn
Journal:  Annu Rev Med       Date:  1988       Impact factor: 13.739

9.  Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water.

Authors:  Jingbo Pi; Hiroshi Yamauchi; Yoshito Kumagai; Guifan Sun; Takahiko Yoshida; Hiroyuki Aikawa; Claudia Hopenhayn-Rich; Nobuhiro Shimojo
Journal:  Environ Health Perspect       Date:  2002-04       Impact factor: 9.031

10.  Arsenic alters the function of the glucocorticoid receptor as a transcription factor.

Authors:  R C Kaltreider; A M Davis; J P Lariviere; J W Hamilton
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

View more
  4 in total

Review 1.  Arsenic exposure in Latin America: biomarkers, risk assessments and related health effects.

Authors:  Tyler R McClintock; Yu Chen; Jochen Bundschuh; John T Oliver; Julio Navoni; Valentina Olmos; Edda Villaamil Lepori; Habibul Ahsan; Faruque Parvez
Journal:  Sci Total Environ       Date:  2011-11-26       Impact factor: 7.963

2.  Therapeutic Potential of Arsenic Trioxide (ATO) in Treatment of Hepatocellular Carcinoma: Role of Oxidative Stress in ATO-Induced Apoptosis.

Authors:  Erika B Dugo; Clement G Yedjou; Jacqueline J Stevens; Paul B Tchounwou
Journal:  Ann Clin Pathol       Date:  2017-01-04

3.  p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study.

Authors:  Chul S Ha; Joel E Michalek; Richard Elledge; Kevin R Kelly; Suthakar Ganapathy; Hang Su; Carol A Jenkins; Athanassios Argiris; Ronan Swords; Tony Y Eng; Anand Karnad; Richard L Crownover; Gregory P Swanson; Martin Goros; Brad H Pollock; Zhi-Min Yuan
Journal:  Mol Oncol       Date:  2015-09-18       Impact factor: 6.603

4.  Occupation and skin cancer: the results of the HELIOS-I multicenter case-control study.

Authors:  Berta Suárez; Gonzalo López-Abente; Carmen Martínez; Carmen Navarro; Maria José Tormo; Stefano Rosso; Simon Schraub; Lorenzo Gafà; Hélène Sancho-Garnier; Janine Wechsler; Roberto Zanetti
Journal:  BMC Public Health       Date:  2007-07-26       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.